Similar articles for PMID: 22884623

Year	Number of Results
2002	1
2005	1
2007	1
2008	2
2009	4
2010	8
2011	9
2012	10
2013	19
2014	19
2015	6
2016	3
2017	5
2018	8
2019	8
2020	8
2021	9
2022	6
2023	2
2024	0

1

Eberlein U, Lassmann M. Eberlein U, et al. Appl Radiat Isot. 2013 Jun;76:70-4. doi: 10.1016/j.apradiso.2012.06.033. Epub 2012 Jul 20. Appl Radiat Isot. 2013. PMID: 22884623 Review.

2

Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.

Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B. Ocak M, et al. Nucl Med Commun. 2013 Nov;34(11):1084-9. doi: 10.1097/MNM.0b013e328364eaab. Nucl Med Commun. 2013. PMID: 23939265

3

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP. Kwekkeboom DJ, et al. Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Endocr Relat Cancer. 2010. PMID: 19995807 Review.

4

(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.

Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. Breeman WA, et al. Semin Nucl Med. 2011 Jul;41(4):314-21. doi: 10.1053/j.semnuclmed.2011.02.001. Semin Nucl Med. 2011. PMID: 21624565 Review.

5

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B. Velikyan I, et al. J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30. J Nucl Med. 2014. PMID: 24379222 Free article. Clinical Trial.

6

Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.

Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, Cui Y, Kataoka Y, Senda M, Watanabe Y. Sako T, et al. Biochem Biophys Res Commun. 2013 Dec 6;442(1-2):79-84. doi: 10.1016/j.bbrc.2013.11.001. Epub 2013 Nov 9. Biochem Biophys Res Commun. 2013. PMID: 24220338

7

Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?

Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Sharma P, et al. AJR Am J Roentgenol. 2013 Dec;201(6):1340-7. doi: 10.2214/AJR.13.10987. AJR Am J Roentgenol. 2013. PMID: 24896203 Review.

8

Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.

Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Demirci E, et al. Nucl Med Commun. 2013 Aug;34(8):727-32. doi: 10.1097/MNM.0b013e328362cca6. Nucl Med Commun. 2013. PMID: 23728519

9

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.

Kulkarni HR, Baum RP. Kulkarni HR, et al. PET Clin. 2014 Jan;9(1):83-90. doi: 10.1016/j.cpet.2013.08.015. PET Clin. 2014. PMID: 25029937 Review.

10

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R. Fanti S, et al. Biomed Pharmacother. 2008 Dec;62(10):667-71. doi: 10.1016/j.biopha.2008.01.010. Epub 2008 Mar 3. Biomed Pharmacother. 2008. PMID: 18358680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year